Generation Bio Co. (GBIO)

3.1800 -0.1700 (-5.07%) 收市：04:00PM EDT

Generation Bio Co.

301 Binney Street
Cambridge, MA 02142
United States
617 655 7500
https://generationbio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 174

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Cameron Geoffrey McDonough M.D.	President, CEO & Director	1.01M	無	1970
Dr. Matthew Norkunas M.B.A., M.D.	Chief Financial Officer	668.21k	無	1978
Dr. Matthew Stanton Ph.D.	Chief Scientific Officer	738.21k	無	1973
Ms. Yalonda Howze J.D.	Chief Legal Officer & Secretary	568.81k	無	1972
Dr. Mark D. Angelino Ph.D.	Co-Founder	無	無	1973
Dr. Robert Kotin Ph.D.	Co-Founder	無	無	1956
Ms. Antoinette Paone M.B.A., M.S.	Chief Operating Officer	無	無	1978
Ms. Jasmin Tower	Chief Human Resources Officer	無	無	無
Dr. Phillip Samayoa Ph.D.	Chief Strategy Officer	無	無	1987

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 2024年5月1日 止，Generation Bio Co. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：8；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。